文献速递前列腺癌

晚期前列腺癌ATM缺失:PARP与ATR抑制剂联合治疗研究

Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors.
PubMed 文献 · Eur Urol · 2020-11-08

本研究利用免疫组化与二代测序分析晚期前列腺癌活检,发现11%(68/631)患者存在ATM蛋白缺失,且部分病例靶向测序未检出。体外模型显示ATM缺失前列腺癌对ATR抑制敏感,对PARP抑制反应不一,联合PARP和ATR抑制显示更优抗肿瘤活性。

要点

  • ATM免疫组化缺失见于11%晚期前列腺癌,存在瘤内异质性。
  • ATM缺失与基因组不稳定相关,但不影响晚期疾病预后。
  • ATM缺失模型对ATR抑制敏感,联合PARP抑制活性更优。

核心结论

  • ATM缺失前列腺癌不一定能被靶向二代测序检出,与基因组不稳定相关,对ATR和PARP联合抑制最敏感。

研究设计与样本

  • 研究采用经验证的免疫组化和二代测序分析晚期前列腺癌活检。
  • 利用CRISPR-Cas9构建ATM功能受损的体外细胞系模型,并在患者来源模型中验证。

主要发现

  • 631例前列腺癌患者中68例(11%)至少一次活检显示ATM免疫组化缺失,存在同步和异时瘤内异质性。
  • 71例ATM缺失活检中46例(65%)通过二代测序检出ATM突变或缺失。
  • ATM免疫组化缺失与晚期疾病不良预后无关,但与基因组不稳定增加相关(NtAI p=0.005;大范围转换 p=0.05)。
  • 体外ATM缺失前列腺癌模型对ATR抑制敏感,对PARP抑制敏感性不一,联合PARP和ATR抑制显示更优抗肿瘤活性。

临床怎么用

  • 对晚期前列腺癌可考虑ATM免疫组化检测以识别ATM缺失亚型。
  • ATM缺失前列腺癌可能从PARP和ATR抑制剂联合治疗中获益。

局限性

  • ATM免疫组化缺失存在瘤内异质性,单次活检可能漏检。
  • 靶向二代测序不能完全检出ATM缺失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond. OBJECTIVE: To characterise ATM-deficient lethal PC and to study synthetic lethal therapeutic strategies for this subset. DESIGN, SETTING, AND PARTICIPANTS: We studied advanced PC biopsies using validated immunohistochemical (IHC) and next-generation sequencing (NGS) assays. In vitro cell line models modified using CRISPR-Cas9 to impair ATM function were generated and used in drug-sensitivity and functional assays, with validation in a patient-derived model. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: ATM expression by IHC was correlated with clinical outcome using Kaplan-Meier curves and log-rank test; sensitivity to different drug combinations was assessed in the preclinical models. RESULTS AND LIMITATIONS: Overall, we detected ATM IHC loss in 68/631 (11%) PC patients in at least one biopsy, with synchronous and metachronous intrapatient heterogeneity; 46/71 (65%) biopsies with ATM loss had ATM mutations or deletions by NGS. ATM IHC loss was not associated with worse outcome from advanced disease, but ATM loss was associated with increased genomic instability (NtAI:number of subchromosomal regions with allelic imbalance extending to the telomere, p = 0.005; large-scale transitions, p = 0.05). In vitro, ATM loss PC models were sensitive to ATR inhibition, but had variable sensitivity to PARP inhibition; superior antitumour activity was seen with combined PARP and ATR inhibition in these models. CONCLUSIONS: ATM loss in PC is not always detected by targeted NGS, associates with genomic instability, and is most sensitive to combined ATR and PARP inhibition. PATIENT SUMMARY: Of aggressive prostate cancers, 10% lose the DNA repair gene ATM; this loss may identify a distinct prostate cancer subtype that is most sensitive to the combination of oral drugs targeting PARP and ATR.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Neeb A, Herranz N, Arce-Gallego S, et al. Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. Eur Urol. 2020. PMID: 33176972. doi:10.1016/j.eururo.2020.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。